The China Mail - Who should get paid for nature's sequenced genes?

USD -
AED 3.672945
AFN 71.515562
ALL 86.94961
AMD 389.939958
ANG 1.80229
AOA 915.999667
ARS 1172.9892
AUD 1.560185
AWG 1.8
AZN 1.687821
BAM 1.720875
BBD 2.018575
BDT 121.46782
BGN 1.725883
BHD 0.37691
BIF 2935
BMD 1
BND 1.306209
BOB 6.908081
BRL 5.674401
BSD 0.99974
BTN 84.489457
BWP 13.685938
BYN 3.271726
BYR 19600
BZD 2.008192
CAD 1.37935
CDF 2872.999879
CHF 0.825695
CLF 0.024788
CLP 951.229649
CNY 7.27135
CNH 7.270995
COP 4243.1
CRC 504.973625
CUC 1
CUP 26.5
CVE 97.62505
CZK 22.028021
DJF 177.720538
DKK 6.590695
DOP 58.849845
DZD 132.651987
EGP 50.839498
ERN 15
ETB 131.849601
EUR 0.883015
FJD 2.25945
FKP 0.7464
GBP 0.750775
GEL 2.744963
GGP 0.7464
GHS 14.125014
GIP 0.7464
GMD 71.502639
GNF 8655.000086
GTQ 7.69911
GYD 209.794148
HKD 7.755845
HNL 25.824976
HRK 6.653403
HTG 130.612101
HUF 357.316013
IDR 16554.05
ILS 3.63992
IMP 0.7464
INR 84.561198
IQD 1310
IRR 42112.49408
ISK 128.649713
JEP 0.7464
JMD 158.264519
JOD 0.709199
JPY 143.008025
KES 129.497429
KGS 87.450184
KHR 4001.999982
KMF 434.49611
KPW 899.962286
KRW 1424.74995
KWD 0.306504
KYD 0.833176
KZT 513.046807
LAK 21614.999723
LBP 89600.000276
LKR 299.271004
LRD 199.577898
LSL 18.629585
LTL 2.95274
LVL 0.60489
LYD 5.454983
MAD 9.26875
MDL 17.160656
MGA 4509.999741
MKD 54.316596
MMK 2099.391763
MNT 3573.279231
MOP 7.987805
MRU 39.750136
MUR 45.159946
MVR 15.410097
MWK 1735.999892
MXN 19.613201
MYR 4.314499
MZN 64.000264
NAD 18.629738
NGN 1602.529753
NIO 36.697423
NOK 10.402335
NPR 135.187646
NZD 1.68454
OMR 0.384943
PAB 0.99974
PEN 3.6615
PGK 4.030499
PHP 55.780526
PKR 280.898478
PLN 3.78005
PYG 8007.144837
QAR 3.640973
RON 4.395801
RSD 103.43097
RUB 82.013774
RWF 1415
SAR 3.751221
SBD 8.361298
SCR 14.237635
SDG 600.502786
SEK 9.662047
SGD 1.305725
SHP 0.785843
SLE 22.790211
SLL 20969.483762
SOS 571.999643
SRD 36.846978
STD 20697.981008
SVC 8.747487
SYP 13001.4097
SZL 18.630308
THB 33.430038
TJS 10.537222
TMT 3.5
TND 2.96375
TOP 2.342099
TRY 38.52375
TTD 6.771697
TWD 32.047014
TZS 2690.000195
UAH 41.472624
UGX 3662.201104
UYU 42.065716
UZS 12945.00049
VES 86.73797
VND 26005
VUV 120.409409
WST 2.768399
XAF 577.175439
XAG 0.030629
XAU 0.000305
XCD 2.70255
XDR 0.71673
XOF 576.000137
XPF 105.649908
YER 244.950087
ZAR 18.60662
ZMK 9001.201184
ZMW 27.817984
ZWL 321.999592
  • RBGPF

    -0.4500

    63

    -0.71%

  • CMSC

    -0.2300

    22.01

    -1.04%

  • JRI

    -0.0200

    12.91

    -0.15%

  • CMSD

    -0.0500

    22.3

    -0.22%

  • RYCEF

    -0.2500

    10

    -2.5%

  • BCC

    -1.2200

    93.28

    -1.31%

  • RELX

    0.8400

    54.63

    +1.54%

  • GSK

    0.8800

    39.85

    +2.21%

  • SCS

    -0.0900

    9.92

    -0.91%

  • RIO

    -1.4800

    59.4

    -2.49%

  • NGG

    -0.0400

    73

    -0.05%

  • BCE

    0.3300

    22.25

    +1.48%

  • VOD

    0.1800

    9.76

    +1.84%

  • BTI

    0.6900

    43.55

    +1.58%

  • AZN

    0.0800

    71.79

    +0.11%

  • BP

    -0.6100

    27.46

    -2.22%

Who should get paid for nature's sequenced genes?
Who should get paid for nature's sequenced genes? / Photo: © AFP/File

Who should get paid for nature's sequenced genes?

Much of the vanilla that flavors our ice cream today is artificial, derived from the genetic signature of a plant that hundreds of years ago was known only to an Indigenous Mexican tribe.

Text size:

The plant's sequenced genomic information, available on public databases, was used as the basis for a synthetic flavoring that today competes with vanilla grown in several countries, mainly by small-scale farmers.

Few, if any, benefits of the lucrative scientific advance have trickled down to the communities that gave us vanilla in the first place.

"Wild genetic resources and pharmaceuticals ... are a multi-multi-billion dollar businesses. They clearly are profitable... that's not in dispute," Charles Barber of the World Resources Institute think tank told AFP.

"A great deal of really valuable information has fed into the system from research and utilization of wild genetic resources. And there is no mechanism currently to compensate the people where this information is coming from" in the form of digitally sequenced data, he added.

Much of the information comes from poor countries.

Fair sharing of the gains derived from digitally-stored genetic sequencing data has been a headache for negotiators at the COP16 biodiversity summit into its second week in Cali, Colombia.

At the last conference, in Montreal in 2022, 196 country parties to the UN's Convention on Biological Diversity (CBD) agreed to create a benefit-sharing mechanism for the use of digital sequence information (DSI).

Two years later, they still need to resolve such basic questions as who pays, how much, into which fund, and to whom does the money go?

- 'Cheap and very fast' -

The issue is a complex one.

There is little debate that genetic data-sharing on mostly free-access platforms is crucial for human advancement through medicine and vaccine development, for example.

But how to quantify the value of the sequenced information itself? And should the first people to discover a plant's particular usefulness be compensated?

"Sequencing technology has become so advanced that you can go with a... handheld device a little bit bigger than a cell phone and you can literally sequence a genome in an hour or two and upload it as you sequence it," Pierre du Plessis, a DSI expert and former negotiator for African countries at the CBD told AFP.

These gene sequences are then uploaded to databases which artificial intelligence can mine for potential leads for product development.

DSI is worth an estimated hundreds of billions of dollars a year. And there is a lot of it out there.

"Once the sequence is put into a public database, generally, no benefit-sharing obligations apply," Nithin Ramakrishnan, a researcher with the Third World Network, an advocacy NGO for developing countries, told AFP in Cali.

"Like when the sandalwood sequence information is available in the database whether India wants to share its sandalwood... with a cosmetic company or not, doesn't matter.

- Mandatory -

A point of contention in Cali is a demand from developing countries that payment for DSI use be mandatory, perhaps through a one-percent levy on profits from drugs, cosmetics or other products.

They also want guarantees of non-monetary benefits such as access to vaccines produced from genetic information sequenced from viruses and other pathogens.

"We want real understanding, sector-specific understanding of what non-monetary benefits will be shared and we want the system to be obligatory -- the users should have some form of obligation to share benefits," said Ramakrishnan.

Another sticking point is access for Indigenous people and local communities to DSI funds.

Developing countries want the information on genetic databases to be traceable and "answerable to governments" of the countries where it comes from, said Ramakrishnan.

But rich nations and many researchers oppose such a model which they fear will be too onerous, potentially putting the brakes on scientific pursuits that could benefit all humankind.

With such divergent points of view, observers are doubtful the Cali COP will emerge with any firm decisions on the outstanding questions by closing time on Friday.

The World Wildlife Fund has said "many more rounds of negotiations appear necessary" on DSI.

Added Barber: "I think it's not going to all get solved here."

Y.Su--ThChM